JMP Securities analyst Silvan Tuerkcan initiated coverage of Solid Biosciences (SLDB) with an Outperform rating and $15 price target Solid is a clinical-stage biotechnology company focused on developing novel AAV-based gene therapies for muscle and cardiac diseases, the analyst tells investors in a research note. The firm views the company as attractively valued at the current market cap, saying its clinical-stage Duchenne muscular dystrophy asset could generate near-term value with upcoming dystrophin expression.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLDB:
- Solid Biosciences management to meet with Piper Sandler
- Solid Biosciences announces collaboration with Mayo Clinic
- Solid Biosciences reports inducement grant under Nasdaq listing rule
- Solid Biosciences Reports Increased Losses Amid R&D Focus
- Solid Biosciences price target lowered to $12 from $15 at JPMorgan